Please try another search
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Ryo Kubota | 57 | 2002 | Founder, Chairman, CEO & President |
Iyo Ichikawa | - | 2023 | Chief Business Officer & Director |
Koichiro Yoshizaki | 57 | 2023 | Independent Outside Director |
Tsutomu Horiuchi | - | 2023 | Independent Outside Director |
Emiko Maki | 49 | 2022 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review